GSK plans to launch five Phase 3 trials for a gynecologic cancer antibody-drug conjugate after sharing early promising data from the asset it licensed from Hansoh Pharma. GSK’s move signals confidence in the program’s early efficacy signal and progression into late-stage registrational plans. The licensing relationship adds a development engine for GSK in oncology, particularly in settings where ADCs are being positioned as next-wave targeted options. The five Phase 3 trials indicate broad expansion of evaluative populations and combinations to strengthen the regulatory package. For biotech peers, the decision reinforces how ADC pipelines are increasingly structured around multiple parallel registrational studies rather than incremental single-trial paths. It also highlights continued reliance on global licensing to speed development cycles. The major near-term catalysts are trial initiation timing and the eventual Phase 3 endpoints that will determine label scope.